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TamoxifenAbstract Objective: To evaluate sonohysterography for the diagnosis of endometrial abnormali-
ties in women treated with tamoxifen for breast cancer.
Patients and methods: We assessed 37 women treated with tamoxifen for breast cancer who under-
went sonohysterography and correlative endometrial biopsy for evaluation of postmenopausal
bleeding or thickened endometrium greater than 8 mm. In 14 patients, endometrial biopsy was fol-
lowed by endovaginal sonography to ensure removal of endometrial pathology. Sonohysterography
ﬁndings were compared with histopathology results.
Results: Sonohysterography ﬁndings coincided with histopathology results in 27 of 37 cases includ-
ing 19 of 23 cases of endometrial polyps, 6 of 8 cases with thickened endometria and two cases had
normal endometrium. Sonohysterography ﬁndings did not coincide with histopathology in 3 of the 14
cases who underwent endovaginal sonography after endometrial biopsy compared to 7 of the 23 cases
who did not undergo such examination and 4 of these missed 7 cases were for endometrial polyps.
Conclusion: Sonohysterography is a useful procedure for the diagnosis of endometrial abnormalities
in tamoxifen-treated women. Endometrial abnormalities are better diagnosed on sonohysterography
than on endometrial biopsy which has the limitation of some missed endometrial polyps, a problem
that may be minimized by performing endovaginal sonography after endometrial biopsy.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine.Open access under CC BY-NC-ND license.
954 H. El Sheikh et al.1. Introduction
Tamoxifen citrate is a selective estrogen receptor modulator
that is widely used for the treatment of breast cancer; it
has also been used recently for the prevention of breast
cancer in high-risk women (1–3). Large trials have shown
that in women with estrogen receptor-positive breast cancer,
tamoxifen treatment for 5 years reduces the annual breast
cancer recurrence rate by 50%, reduces the annual death
rate by 28%, and decreases the risk of contralateral breast
cancer by 39% regardless of receptor status (1–3). The
Breast Cancer Prevention Trial documented a 50% reduc-
tion in the rate of breast cancer among high-risk women
who received tamoxifen treatment as compared with control
subjects (2).
Tamoxifen inhibits estrogen-dependent tumor growth by
competing with estrogen at receptor sites. This competition
for receptor sites may result in either antiestrogenic or weakly
estrogenic effects, depending on tissue site and receptor status.
In the uterus, tamoxifen has an estrogenic effect that produces
endometrial abnormalities such as endometrial polyps, hyper-
plasia and carcinoma (4–7).
The beneﬁts of tamoxifen for breast cancer treatment far
outweigh any potential endometrial abnormalities that may
occur (2). However, because tamoxifen-treated women have
an increased frequency of endometrial neoplasia and prema-
lignant conditions such as atypical hyperplasia, it is impor-
tant to develop adequate methods for diagnosing
endometrial complications resulting from tamoxifen and
there is interest in screening this population for endometrial
abnormalities. The value of screening has not been estab-
lished, and the optimum method of surveillance has not
been determined (2,4–7). Several groups of investigators
have shown the usefulness of sonohysterography for the
diagnosis of endometrial abnormalities, particularly in wo-
men with abnormal uterine bleeding (8–12).
We designed this study to evaluate sonohysterography
for the diagnosis of endometrial abnormalities in women
who are undergoing tamoxifen treatment for breast
cancer.
2. Patients and methods
This prospective study was conducted from April 2008 to
October 2012 for 39 tamoxifen-treated women referred for
sonohysterography. Thirty-seven sonohysterograms were
completed and two studies were unsuccessful because of dif-
ﬁcult cannulation of the cervix and were excluded from the
study. All women had been undergoing tamoxifen therapy
for a mean of 2.5 years (range, 1–4 years). The mean
patient age was 48 years (range, 37–72 years). Women were
referred for sonohysterography because of postmenopausal
bleeding (n= 6) and endometrial thickening greater than
8 mm detected on preliminary transvaginal sonography
(n= 31). Endometrial thickness measurements were
obtained in the anteroposterior dimension on sagittal
images, and any endometrial cystic spaces or polyps were
also documented.
Sonohysterography was performed by an experienced radi-
ologist using an endovaginal curved 4–9 MHz transducer (of
Medison SONOACE 6000 C unit). The procedure wasexplained to the patient in detail and informed consent had
been obtained for all studies.
Sonohysterography was performed in a standard manner as
previously described (13). All studies were performed with a 5
French or 7 French Zinnanti HS catheter (Thomas medical.
Inc. Blomet, waterton industrial estate, Bridgend, CF13XA,
UK). Brieﬂy, after cleaning the cervix with povidone-iodine,
a sterile 5 or 7-French occlusive balloon catheter that has been
ﬂushed with sterile saline to eliminate the air is then guided
into the endocervical canal. The catheter is advanced past
the external cervical os for a variable distance (usually
2–7 cm) and the catheter balloon was ﬁlled with ﬂuid to avoid
artifact. The speculum is then carefully removed, allowing the
catheter to remain in place. Transvaginal scanning is then
performed during the instillation of sterile saline solution.
After assessment of the fundus and upper uterine segment,
the balloon was decompressed while injecting more ﬂuid to en-
sure adequate visualization of the lower uterine segment. The
amount of saline solution required for the adequate distention
of the endometrial cavity varied, ranging from approximately
10 to 40 ml depending on cervical leakage. The examination
usually lasts 5–10 min.
The presence of endometrial thickening, polyps, suben-
dometrial cysts and other abnormalities was recorded. Endo-
metrial measurements were obtained in the sagittal plane.
The anterior and posterior single thickness measurements were
added together for a double-layer endometrial measurement.
For tamoxifen-treated women, a double-layer thickness of
8 mm or less was considered normal (6,7,14).
On sonohysterography, polyps appear as echogenic,
smooth, intracavitary masses outlined by ﬂuid (15,16). Color
Doppler images may show a single feeding artery at the base
of attachment, a ﬁnding frequently seen with polyps (17).
All sonohysterograms were followed by endometrial
biopsy with dilatation and curettage and the sonohysterog-
raphy ﬁndings were compared with histopathology results.
After performing sonohysterography for 23 patients and
comparing their sonohysterography ﬁndings with histopa-
thology results, we found that sonohysterographic ﬁndings
did not coincide with histopathology results in 7 patients
and 4 of them had characteristic sonohysterographic
appearance for endometrial polyps but normal endometria
were found at histopathology. We identiﬁed these 23
patients as group A.
We thought that performing endovaginal sonography in
the operation room (OR) immediately after endometrial
biopsy aiming to obtain normal endometrial thickness (less
than 5 mm) on vaginal sonography may ensure removal of
any missed endometrial pathology. Therefore, in the
remaining 14 patients, endometrial biopsy was immediately
followed by transvaginal sonography in the OR and the
procedure was done by the same radiologist and the same
US machine used in pre-operative assessment in the radiol-
ogy department which was brought into the OR for each
of the 14 patients. The sonographic ﬁndings were compared
with those seen in the preliminary endovaginal sonography
and sonohysterography and re-curettage were done for
cases with residual thickened endometrium. We identiﬁed
these 14 patients as group B.
Sonohysterography ﬁndings for each group and for all
patients were compared with histopathology results after
dilatation and curettage.
Fig. 1A. 46-Year-old woman undergoing tamoxifen treatment
for 3 years. Preliminary sagittal transvaginal sonogram shows
thickened endometrium with double-layer endometrial thickness
measuring 12 mm (short arrows) and suspected mass within the
endometrial cavity (long arrow).
Fig. 1B. 46-Year-old woman undergoing tamoxifen treatment
for 3 years. Sagittal sonohysterogram with image taken during
instillation of saline into the uterine cavity shows delineation of
endometrial polyp (M) with its pedicle at the posterior wall (long
arrow). The injected ﬂuid is seen as echogenic ring around the
polyp (short arrows).
Sonohysterography for endometrial abnormalities as per MS 9553. Results
All sonohysterography examinations were well tolerated by the
patients and no complicationswere encountered. Sonohysterog-
raphy revealed endometrial polyps in 23 cases (62%) and their
mean dimension was 27 mm (range, 4–50 mm), thickened endo-
metrium greater than 8 mm in 8 cases (21.5%), subendometrial
cysts in 4 cases (11%) and normal endometrial in two cases
(5.5%). Sonohysterography ﬁndings are presented in Table 1.
Sonohysterography ﬁndings coincided with histopathology
results in 27 of the 37 cases including 19 of 23 cases of endo-
metrial polyps, 6 of the 8 cases with thickened endometria
(all had endometrial hyperplasia, two were simple and 4 were
atypical hyperplasia) and two cases had normal endometrium
both at sonohysterography and histopathology. No cases of
endometrial carcinoma were seen. The sonohysterography
ﬁndings are compared with histopathology results for all 37
patients in Table 2.
The 27 cases for whom sonohysterography coincided with
histopathology were 16 cases in group A (23 patients who did
not undergo intra-operative endovaginal sonography after
endometrial biopsy) and 11 cases in group B (14 patients who
underwent intra-operative endovaginal sonography after endo-
metrial biopsy). In group A patients, 11 of 15 endometrial pol-
yps shown on sonohysterography were conﬁrmed on
histopathology (Fig. 1A–C). Four of six patients with thickened
endometria on sonohysterography had endometrial hyperpla-
sia, one of which was simple and the other three were atypical
hyperplasia (Fig. 3A and B). One patient had normal endome-
trium both at sonohysterography and histopathology. In group
B patients, all eight endometrial polyps shown on sonohysterog-
raphy were conﬁrmed on histopathology and two of these pa-
tients underwent re-curettage due to residual thickened
endometrium on intra-operative endovaginal sonography done
after endometrial biopsy (Fig. 2A–C). The two patients with
thickened endometria on sonohysterography had endometrial
hyperplasia, one of which was simple and the other atypical
hyperplasia. One patient had normal endometrium both at
sonohysterography and histopathology.
The remaining 10 cases with discordant sonohysterography
and histopathology were 7 cases in group A and 3 cases inTable 1 Findings of sonohysterograms of 37 women treated
with tamoxifen.
Finding Number Percentage (%)
Polyps 23 (62)
Thickened endometrium 8 (21.5)
Subendometrial cysts 4 (11)
Normal endometrium 2 (5.5)
Total 37 (100)
Table 2 Sonohysterography ﬁndings compared with histopathology
Histopathology Polyp Sonohysterograph
Thickened endome
Polyp 19 1
Hyperplasia 0 6
Normal 4 1
Total 23 8group B. The missed 7 cases of group A were 4 cases of endo-
metrial polyps on sonohysterograms but normal endometria
were found at histopathology (Fig. 4), two cases with thick-
ened endometria on sonohysterography but at histopathology,
one case had an endometrial polyp and the other had normal
endometrium, the last case had subendometrial cyst on sono-
hysterography, but histopathology revealed endometrial pol-
yps. All three missed cases in group B had subendometrial
cysts at sonohysterograms but at histopathology, two had
endometrial polyps and the third had normal endometrium.in all 37 patients.
y
trium Subendometrial cysts Normal
3 0
0 0
1 2
4 2
Fig. 1C. 46-Year-old woman undergoing tamoxifen treatment
for 3 years. Sagittal sonohysterogram with image taken after
instillation of saline into the uterine cavity shows large endome-
trial polyp (M) measured 25 · 20 mm. The polyp was seen as
smooth echogenic mass projecting into the endometrial cavity
outlined by ﬂuid. The polyp was conﬁrmed at histopathology.
Fig. 3A. 47-Year-old woman undergoing tamoxifen treatment
for 2 years. Preliminary sagittal transvaginal sonogram shows
uneven thickening of the endometrium measuring 18 mm at the
fundus (arrows).
Fig. 3B. 47-Year-old woman undergoing tamoxifen treatment
for 2 years. Sagittal sonohysterogram shows uneven thickening of
the endometrium and irregularity of the anterior endometrial
lining at the fundus (arrows). Histopathology shows atypical
endometrial hyperplasia.
Fig. 2A. 52-Year-old woman undergoing tamoxifen treatment
for 3 years. Sagittal sonohysterogram reveals three variable sized
endometrial polyps (arrows) ranging from 5 to 20 mm. Polyps are
seen as smooth echogenic masses projecting into the endometrial
cavity outlined by ﬂuid (two anterior and one posterior). Polyps
were conﬁrmed at histopathology.
Fig. 2B. 52-Year-old woman undergoing tamoxifen treatment
for 3 years. Intra-operative sagittal transvaginal sonogram after
endometrial biopsy shows smooth endometrium (arrows) with
normal thickness denoting successful removal of all polyps.
Fig. 2C. 52-Year-old woman undergoing tamoxifen treatment
for 3 years. Histopathology reveals increased number of endome-
trial glands, columnar non-secretory cells and spinle stoma cells
consistent with hyperplastic endometrial polyps.
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thology results for group A and group B patients in Tables 3
and 4, respectively.4. Discussion
The increased endometrial thickness observed in tamoxifen-
treated women is caused by the estrogen agonist effect of
tamoxifen, which is similar to hormone replacement therapy.
Debate exists regarding the normal range of endometrial thick-
ness for women treated with tamoxifen. An endometrial thick-
ness of less than 5 mm essentially excludes the presence of
Fig. 4. 45-Year-old woman undergoing tamoxifen treatment for
3 years. Sagittal sonohysterogram reveals small anterior endome-
trial polyp (arrow) measured 5 mm. Histopathology shows
negative ﬁnding (was negative for polyp).
Sonohysterography for endometrial abnormalities as per MS 957endometrial abnormalities (18–20). Most asymptomatic wo-
men treated with tamoxifen have endometrial thickness
exceeding 5 mm, and endometrial thickness in those women
is greater than that in postmenopausal control subjects
(6,21). Lin et al. (14) reported that 91 of 112 asymptomatic
post-menopausal women undergoing hormone replacement
therapy had endometrial thickness greater than 8 mm, and
the authors recommended biopsy for asymptomatic women
with endometrial thickness greater than 8 mm. Using the 8-
mm cutoff value, approximately half of the women treated
with tamoxifen will have transvaginal sonography endometrial
measurements in the normal range (6,22). Our patient popula-
tion included tamoxifen-treated women with postmenopausal
bleeding and tamoxifen-treated women with endometrial
thickening greater than 8 mm detected on preliminary trans-
vaginal sonography but who were otherwise asymptomatic.
Endometrial polyps were the most frequent ﬁnding in our
study. Using sonohysterography, we showed endometrial pol-
yps in 62% of cases. Our results are similar to those of Timm-
erman et al. (22) and Lucy et al. (23) in studies comparingTable 3 Sonohysterography ﬁndings compared with histopatholog
operative endovaginal sonography after endometrial biopsy).
Histopathology Polyp Sonohysterograph
Thickened endome
Polyp 11 1
Hyperplasia 0 4
Normal 4 1
Total 15 6
Table 4 Sonohysterography ﬁndings compared with histopathology
endovaginal sonography after endometrial biopsy).
Histopathology Polyp Sonohysterography
Thickened Endome
Polyp 8 0
Hyperplasia 0 2
Normal 0 0
Total 8 2sonohysterography with hysteroscopy. Other investigators
have reported a much lower prevalence of polyps, in the range
of 33% (6,21). This discrepancy may be explained by sampling
methods. Kedar et al. (21) suggested that the prevalence of
endometrial polyps may be underestimated by reports that
use endometrial biopsy as the standard of reference.
Previous studies have shown discrepancy between sonohys-
terography and hysteroscopy for the diagnosis of endometrial
polyps raising the issue of gold standard (23,24). Lucy et al.
(23) found that 5 of 31 endometrial polyps diagnosed using
sonohysterography were not conﬁrmed by operative hysteros-
copy and histopathology despite their classic appearance. Sim-
ilar results were shown by Schwarzler et al. (24) who reported
that operative hysteroscopy missed two of 25 polyps detected
using sonohysterography. Authors of these studies suggested
that an endometrial polyp may be expelled spontaneously in
the interval between sonohysterography and hysteroscopy.
Alternatively, the discrepancy may be related to hysteroscopic
technique. Although hysteroscopy has a wide ﬁeld of view,
visualization may be limited if the scope is advanced beyond
a mobile polyp.
Similar limitations of endometrial biopsy for the diagnosis
of endometrial abnormalities in tamoxifen-treated women
mainly endometrial polyps have been reported by other studies
(23,25). Lucy et al. (23) documented endometrial abnormalities
on sonohysterography in 12 of 19 (63%) sonohysterograms
that had negative correlative endometrial biopsy; 10 of these
abnormalities were endometrial polyps. Similar results were
reported by Dubinsky et al. (25). In our study, 4 of the 23
patients who had sonohysterographic appearance for endome-
trial polyps showed normal endometria at histopathology. We
suggested that endometrial biopsy may obtain tissue from the
adjacent endometrium and miss a mobile polyp or the polyp
was small.
In our study, sonohysterography ﬁndings coincided with
histopathology results in 27 of the 37 cases including 19 of
23 cases of endometrial polyps, 6 of 8 cases with thickened
endometria (all had endometrial hyperplasia) and two cases
had normal endometrium both at sonohysterography and his-
topathology. The remaining 10 cases with discordant sonohys-y in group A patients (23 patients who did not undergo intra-
y
trium Subendometrial cysts Normal
1 0
0 0
0 1
1 1
in group B patients (14 patients who underwent intra-operative
trium Subendometrial Cysts Normal
2 0
0 0
1 1
3 1
958 H. El Sheikh et al.terography and histopathology were 3 of the 14 cases who
underwent endovaginal sonography after endometrial biopsy
aiming to ensure removal of any missed endometrial pathology
and 7 of the 23 cases who did not undergo such examination
and 4 of these missed 7 cases were for the previously men-
tioned missed endometrial polyps. Among the 14 cases who
underwent endovaginal sonography after endometrial biopsy,
all 8 cases of endometrial polyps shown on sonohysterography
were conﬁrmed on histopathology, two of these patients
underwent re-curettage due to residual thickened endome-
trium. Therefore, we thought that performing endovaginal
sonography in the operation room after endometrial biopsy
can minimize the limitation of endometrial biopsy for the diag-
nosis of endometrial abnormalities particularly endometrial
polyps. Further prospective studies involving large groups of
patients are still required to assess the added value of perform-
ing endovaginal sonography in the operation room after endo-
metrial biopsy in tamoxifen-treated women.
We found four cases of premalignant condition (atypical
endometrial hyperplasia) in our series but no cases of endome-
trial carcinoma. This conforms to Ascher et al., (7) and Lucy
et al., (23) who reported that although estimates are that
approximately 50% of tamoxifen-treated women will have
endometrial abnormalities, most of these abnormalities are be-
nign. Surveillance is done to exclude endometrial cancer, but
the degree of risk should not be overestimated. The annual risk
of endometrial carcinoma in tamoxifen-treated women is in the
range of 1.6 in 1000 individuals (2). Endometrial carcinoma is
more frequent with prolonged tamoxifen use (>5 years), and
patients generally present with vaginal bleeding (4,6). Many
studies have shown that 80–88% of tamoxifen-associated
endometrial cancers are early tumors (FIGO [International
Federation of Gynecology and Obstetrics] stage 1) (2,4,26).
5. Conclusion
Sonohysterography is a useful procedure for the diagnosis
of endometrial abnormalities in tamoxifen-treated women.
Endometrial abnormalities mainly endometrial polyps are better
diagnosed on sonohysterography than on endometrial biopsy
which has the limitation of some missed endometrial polyps, the
problem may be minimized by performing immediate intra-
operative endovaginal sonography after endometrial biopsy.
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